Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

United States Life Science Tools Market (2026-2031) - Rising R&D Investment to Drive Growth

globenewswire.com
A Agilent Technologies is mentioned as a company within the United States Life Science Tools market, which is projected to grow. The article does not provide specific sentiment towards Agilent itself, but its products are part of the growing market. BDX Becton, Dickinson and Company is listed as a company in the United States Life Science Tools market, which is expected to grow. No specific sentiment is expressed for BDX, but it is part of the expanding industry. BIO Bio-Rad Laboratories is identified as a participant in the United States Life Science Tools market, which is forecast to expand. The article does not offer a specific sentiment for Bio-Rad, but it is positioned within a growing sector. BKE Bio-Techne is mentioned as a company within the United States Life Science Tools market, which is projected to grow. The article does not provide specific sentiment towards Bio-Techne itself, but its products are part of the growing market. BRKR Bruker Corporation is listed as a company in the United States Life Science Tools market, which is expected to grow. No specific sentiment is expressed for Bruker, but it is part of the expanding industry. DHR Danaher Corporation is identified as a participant in the United States Life Science Tools market, which is forecast to expand. The article does not offer a specific sentiment for Danaher, but it is positioned within a growing sector. ILMN Illumina is mentioned as a company within the United States Life Science Tools market, which is projected to grow. The article does not provide specific sentiment towards Illumina itself, but its sequencing systems are a key growth area. MRK Merck KGaA (MilliporeSigma) is listed as a company in the United States Life Science Tools market, which is expected to grow. No specific sentiment is expressed for Merck KGaA, but it is part of the expanding industry. PACB Pacific Biosciences is mentioned as a company within the United States Life Science Tools market, which is projected to grow. The article does not provide specific sentiment towards Pacific Biosciences itself, but its sequencing technologies are relevant to market growth. QGEN QIAGEN N.V. is listed as a company in the United States Life Science Tools market, which is expected to grow. No specific sentiment is expressed for QIAGEN, but it is part of the expanding industry. TMO Thermo Fisher Scientific Inc. is identified as a participant in the United States Life Science Tools market, which is forecast to expand. The article does not offer a specific sentiment for Thermo Fisher, but it is positioned within a growing sector. WAT Waters Corporation is mentioned as a company within the United States Life Science Tools market, which is projected to grow. The article does not provide specific sentiment towards Waters Corporation itself, but its chromatography and mass spectrometry systems are key growth areas.

United States Life Science Tools Market (2026-2031) - Rising R&D Investment to Drive Growth Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "United States Life Science Tools - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

United States Life Science Tools Market to Reach USD 70.19 Billion by 2031

The United States life science tools market is projected to grow from USD 52.51 billion in 2025 and USD 54.65 billion in 2026 to USD 70.19 billion by 2031, registering a compound annual growth rate of 5.13% from 2026 to 2031. Market expansion is being supported by rising biopharmaceutical research and development activity, increasingly complex therapeutic pipelines, precision medicine adoption, and growing demand for high-throughput genomic, proteomic, and cell biology technologies.

The market encompasses instruments, consumables and reagents, software, and services used across drug discovery and development, clinical diagnostics, precision medicine, academic research, bioprocessing, and advanced therapies. Pharmaceutical and biotechnology companies remain major end users, alongside hospitals, diagnostic laboratories, research institutes, contract research organizations, and development and manufacturing service providers.

Complex Biopharmaceutical Pipelines Drive Demand for Advanced Tools

Biopharmaceutical programs in oncology, rare diseases, and advanced therapeutic modalities are becoming more analytically demanding. Companion diagnostic development, multi-omics patient stratification, and expanded chemistry, manufacturing, and controls characterization are increasing the number and sophistication of life science tools required for each drug candidate.

Rare disease research is also strengthening demand for sensitive genomic and proteomic workflows. Small patient populations make data quality especially important, encouraging laboratories to invest in technologies capable of generating reliable results from limited samples. At the same time, pressure to reduce drug development costs and timelines is accelerating the adoption of automated, scalable, and high-throughput laboratory platforms.

The growing development of bispecific antibodies, antibody-drug conjugates, cell therapies, and other complex modalities is widening the use of orthogonal analytical methods. Native mass spectrometry, mass photometry, microfluidic capillary electrophoresis, advanced chromatography, and high-resolution imaging are increasingly being incorporated across research, process development, manufacturing, and quality control.

Precision Medicine Expands Genomic and Proteomic Workflows

The continued commercialization of precision medicine is generating durable demand for clinical genomic and proteomic tools beyond traditional discovery laboratories. Companion diagnostics are helping biopharmaceutical and diagnostic developers coordinate clinical, regulatory, and commercialization strategies. Research examining U.S. oncology approvals found that companion diagnostic use was associated with a mean reduction of 379.5 days in clinical development time, reinforcing the value of integrated testing platforms.

Expanded reimbursement for sensitive molecular testing is also supporting market growth. In May 2026, Medicare coverage broadened for the Personalis NeXT Personal test in treatment monitoring for Stage II-III triple-negative and HER2-positive breast cancer. As laboratories add liquid biopsy workflows to existing sequencing infrastructure, clinical sites are generating recurring demand for sequencing reagents, library preparation kits, sample preparation products, and data analysis solutions.

Capital Costs Remain a Key Market Restraint

High instrument costs and constrained laboratory budgets are slowing equipment replacement cycles at academic core facilities, hospital laboratories, and mid-sized biotechnology companies. A laboratory purchasing survey conducted in fall 2025 found that 81.1% of laboratories entered 2026 with cost reduction as a primary operating priority, while 81.9% were willing to move away from established brands in favor of a lower total cost of ownership.

This purchasing environment is increasing price competition and encouraging interest in lower-capital and instrument-free workflows. Integrated automation platforms may also require lengthy installation, validation, and training periods, creating adoption challenges for laboratories unable to accommodate workflow interruptions. Instrument-as-a-service agreements and reagent rental programs are helping reduce upfront costs, although these financing models remain more accessible within larger supplier relationships.

Additional factors shaping the United States life science tools market include declining next-generation sequencing costs, higher multi-omics throughput, growing adoption of spatial biology and single-cell workflows, and shortages of specialists in bioinformatics and field service.

Consumables, Reagents, and Genomic Technologies Lead Growth

Instruments accounted for 48.87% of the United States life science tools market in 2025, supported by demand for chromatography systems, mass spectrometers, sequencing platforms, flow cytometers, and laboratory automation. Mass spectrometry and sequencing systems are showing strong revenue momentum as clinical laboratories modernize their platforms and cell and gene therapy manufacturers expand analytical capacity.

Consumables and reagents are forecast to record the fastest product growth, advancing at a 6.98% CAGR through 2031. Recurring demand is rising as installed instruments support more frequent oncology testing, cell therapy development, and multi-omics analysis. Sequencing reagents, library preparation kits, antibodies, immunoreagents, and cell culture media are expected to remain important growth categories. Software and services are also expanding as bioinformatics, laboratory information management systems, and workflow informatics become essential to data-intensive research and clinical programs.

Proteomic technologies represented 33.83% of market revenue in 2025, reflecting the central role of mass spectrometry, chromatography, and immunoassays in biologics development and quality control. Genomic technologies are projected to grow at a 7.46% CAGR through 2031, making them the fastest-growing technology category. Falling sequencing costs and wider clinical adoption of next-generation sequencing in oncology and inherited disease testing are broadening the customer base.

Cell biology tools are benefiting from continued investment in cell and gene therapy, while multi-omics, single-cell analysis, spatial transcriptomics, and spatial proteomics are moving from academic research into more structured pharmaceutical research and development workflows. Together, these trends are expected to sustain long-term growth across the United States life science tools market through 2031.

Key Topics Covered:

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 United States Biopharma R&D Intensity and Pipeline Complexity

4.2.2 NIH Extramural Funding and Translational Program Spend

4.2.3 Precision Medicine Scaling Across Oncology and Rare Disease

4.2.4 NGS Cost Compression and Multi-Omics Throughput Gains

4.2.5 Spatial Biology and Single-Cell Workflow Adoption

4.2.6 Trusted-Source Procurement Shifts After Biosecurity Scrutiny

4.3 Market Restraints

4.3.1 Advanced Instrument CAPEX and Recurring Consumables Burden

4.3.2 LDT Regulatory Phaseout Raises Validation and Compliance Costs

4.3.3 NIH Grant Timing Volatility for Academia-Led Purchases

4.3.4 Specialist Talent Shortages in Bioinformatics and Field Service

4.4 Value / Supply-Chain Analysis

4.5 Regulatory Landscape

4.6 Technological Outlook

4.7 Porter's Five Forces Analysis

4.7.1 Threat of New Entrants

4.7.2 Bargaining Power of Suppliers

4.7.3 Bargaining Power of Buyers

4.7.4 Threat of Substitutes

4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts

5.1 By Product

5.1.1 Instruments

5.1.1.1 Chromatography Systems

5.1.1.2 Mass Spectrometry Systems

5.1.1.3 Flow Cytometers and Cell Sorters

5.1.1.4 Sequencing Systems

5.1.1.5 Microscopy and Imaging Systems

5.1.1.6 PCR and qPCR Systems

5.1.1.7 Liquid Handling and Lab Automation Systems

5.1.1.8 Electrophoresis and Separation Systems

5.1.1.9 Centrifuges and Sample Preparation Systems

5.1.2 Consumables and Reagents

5.1.2.1 Assay Kits

5.1.2.2 Antibodies and Immunoreagents

5.1.2.3 Cell Culture Media and Sera

5.1.2.4 Sequencing Reagents and Library Preparation Kits

5.1.2.5 PCR Reagents and Enzymes

5.1.2.6 Chromatography Columns and Solvents

5.1.2.7 Sample Preparation and Purification Kits

5.1.2.8 Microplates, Tubes, Tips and Lab Plastics

5.1.3 Software and Services

5.1.3.1 Bioinformatics and Data Analysis Software

5.1.3.2 LIMS and Workflow Informatics

5.1.3.3 Instrument Service and Maintenance

5.1.3.4 Contract Assay and Research Services

5.2 By Technology

5.2.1 Genomic Technology

5.2.1.1 Next-Generation Sequencing

5.2.1.2 Sanger Sequencing

5.2.1.3 PCR and qPCR

5.2.1.4 Microarrays

5.2.1.5 Digital PCR

5.2.2 Proteomic Technology

5.2.2.1 Mass Spectrometry

5.2.2.2 Protein Microarrays

5.2.2.3 Chromatography

5.2.2.4 Immunoassays

5.2.3 Cell Biology Technology

5.2.3.1 Cell Culture

5.2.3.2 Flow Cytometry

5.2.3.3 High-Content Screening

5.2.3.4 Imaging and Microscopy

5.2.3.5 Cell Line Development Tools

5.2.4 Multi-omics and Spatial Biology

5.2.4.1 Single-Cell Omics

5.2.4.2 Spatial Transcriptomics

5.2.4.3 Spatial Proteomics

5.2.4.4 Integrated Multi-omics Informatics

5.2.5 Analytical and Separation Technology

5.2.5.1 Spectroscopy

5.2.5.2 Electrophoresis

5.2.5.3 Centrifugation

5.2.5.4 Liquid Handling and Automation

5.3 By Application

5.3.1 Drug Discovery and Development

5.3.1.1 Target Identification and Validation

5.3.1.2 Hit Discovery and Screening

5.3.1.3 Preclinical Translational Research

5.3.1.4 CMC and Process Development Analytics

5.3.2 Clinical Diagnostics and Precision Medicine

5.3.2.1 Oncology Testing

5.3.2.2 Rare Disease and Inherited Disease Testing

5.3.2.3 Infectious Disease Testing

5.3.2.4 Companion Diagnostics Development

5.3.3 Academic and Government Research

5.3.3.1 Basic Research

5.3.3.2 Translational Research

5.3.3.3 Core Facilities

5.3.4 Bioprocessing and Advanced Therapies

5.3.4.1 Cell Therapy Development

5.3.4.2 Gene Therapy Development

5.3.4.3 Biologics and Biosimilars Analytics

5.3.4.4 Vaccine Research and Manufacturing Support

5.4 By End User

5.4.1 Pharmaceutical and Biotechnology Companies

5.4.2 Academic and Research Institutes

5.4.3 Hospitals and Diagnostic Laboratories

5.4.4 Contract Research Organizations and CDMOs

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)

6.3.1 Agilent Technologies

6.3.2 Becton, Dickinson and Company

6.3.3 Bio-Rad Laboratories

6.3.4 Bio-Techne

6.3.5 Bruker Corporation

6.3.6 Danaher Corporation

6.3.7 Eppendorf

6.3.8 Illumina

6.3.9 Merck KGaA (MilliporeSigma)

6.3.10 Oxford Nanopore Technologies

6.3.11 Pacific Biosciences

6.3.12 QIAGEN N.V.

6.3.13 Revvity

6.3.14 Roche

6.3.15 Sartorius AG

6.3.16 Standard BioTools

6.3.17 Thermo Fisher Scientific Inc.

6.3.18 Waters Corporation

6.3.19 ZEISS

6.3.20 10x Genomics

7 Market Opportunities & Future Outlook

7.1 White-space & Unmet-need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/hlas5c

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.